The need for sensitive, robust, portable and inexpensive biosensing platforms is of significant interest in clinical applications for disease diagnosis and treatment monitoring at the point-of-care (POC) settings. Rapid, accurate POC diagnostic assays play a crucial role in developing countries, where there are limited laboratory infrastructure, trained personnel and financial support. However, current diagnostic assays commonly require long assay time, sophisticated infrastructure and expensive reagents that are not compatible with resource-constrained settings. Although paper and flexible material-based platform technologies provide alternative approaches to develop POC diagnostic assays for broad applications in medicine, they have technical challenges integrating to different detection modalities. Here, we address the limited capability of current paper and flexible material-based platforms by integrating cellulose paper and flexible polyester films as diagnostic biosensing materials with various detection modalities through the development and validation of new widely applicable electrical and optical sensing mechanisms using antibodies and peptides. By incorporating these different detection modalities, we present selective and accurate capture and detection of multiple biotargets including viruses (Human Immunodeficieny Virus-1), bacteria (Escherichia coli and Staphylococcus aureus) and cells (CD4+ T lymphocytes) from fingerprick volume equivalent of multiple biological specimens such as whole blood, plasma and peritoneal dialysis effluent with clinically relevant detection and sensitivity.
Rapid diagnosis has broad applications in multiple disciplines including clinical medicine, immunoassays, food safety, environmental monitoring and veterinary medicine1,2,3,4,5. Among these applications, development of easy-to-use, rapid and inexpensive point-of-care (POC) diagnostic assays, particularly in resource-constrained settings, remains an urgent need. POC diagnostics facilitate timely opportunities for detection and control of disease, treatment monitoring and counseling in both developed and developing countries to solve real world healthcare problems6,7. Paper and flexible material-based platform technologies have created an exciting avenue in the area of POC diagnostics. These technologies have also potential to shift the paradigm in developing diagnostic assays, particularly for the developing world, as they are thin, light, flexible, inexpensive and materials are readily available around the world. These platforms are easy-to-fabricate, mass-producible, easy-to-use and disposable1,8. Paper-based platforms can also absorb fluid samples through capillary effect and be incinerated for convenient and safe disposal8. Therefore, these platforms provide attractive strategies for developing affordable tools with broad applications such as drug development, water and environment quality monitoring and infectious diseases diagnosis in resource-constrained settings8,9. Current paper and flexible material-based platforms utilizing colorimetric10, fluorometric11 and electrochemical approaches12 require complex labeling steps to amplify the signal. Further, these platforms need expensive infrastructure and skilled personnel for their fabrication and operation, which are significant challenges for their deployment into the POC settings. Although there has been a considerable number of studies on paper and flexible material-based biosensors, there is a need for studies demonstrating (i) their applicability to different detection modalities such as electrical and optical sensing and (ii) their detection capability for various biotargets from a variety of clinical sample types including whole blood, serum, saline, dialysis effluent or lysates with high sensitivity and specificity. By employing three different paper and flexible material-based platforms incorporated with electrical and optical sensing modalities, we address these major challenges with specific examples for their broad use as diagnostic device materials.
In this manuscript, we demonstrate different paper and flexible material-based diagnostic platforms with biosensing applications to detect various bioagents in whole blood, serum and peritoneal fluid. These distinct platforms have been integrated with sensing modalities including impedance spectroscopy of biotargets, nanoparticle aggregation using a mobile phone-based detection system and lensless shadow imaging technology that do not require any signal amplification. As clinical disease models, we present applications of paper and flexible material-based platforms focusing on (i) detection of Human Immunodeficiency Virus-1 (HIV-1) by capturing and detecting multiple HIV-1 subtypes, (ii) CD4+ T lymphocytes and (iii) detection of bacterial infections such as Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) in various clinical matrices with high sensitivity and specificity. Thus, we demonstrate that paper and flexible material-based platforms can be widely applied to a variety of settings including medical diagnostic and biology laboratories. The combination of these sensing mechanisms on paper and flexible materials offers a promising opportunity to create diagnostic assays that meet the requirements of POC disease detection and treatment monitoring.
HIV detection on a flexible polyester film-based electrical sensing platform
A flexible polyester film with two rail silver electrodes in microfluidic channels was employed as an electrical sensing platform to detect viruses (HIV-1) through viral lysate impedance spectroscopy (Figs. 1A, S1 and S2). Here, biological samples spiked with HIV-1 were used as a clinical disease model for HIV-1 diagnosis. HIV-1 spiked in samples were first captured and isolated off-chip using magnetic beads conjugated with biotinylated polyclonal anti-gp120 antibodies. To detect captured HIV-1, we evaluated the impedance magnitude and phase spectra of viral lysate samples for multiple HIV-1 subtypes including A, B, C, D, E, G and panel over a range of frequencies between 100 Hz and 1 MHz (Figs. 2A and 2B). Our preliminary experiments were performed using HIV-spiked into Dulbecco's phosphate buffered saline (DPBS) samples. Captured viruses were then detected through viral lysate impedance spectroscopy on the platform. Viral lysis step increases the electrical conductivity and decreases the bulk impedance magnitude of the solution. An equivalent electronic circuit model was developed to calculate the impedance magnitude of the viral lysate samples (Fig. S3) as earlier developed13. The average impedance magnitude spectra of the viral lysate samples for all HIV-1 subtypes were below the average impedance magnitude spectrum of the control samples for frequencies between 100 Hz and 100 kHz (Fig. 2A). Control samples were prepared by mixing HIV-free DPBS and conjugated magnetic beads. The impedance magnitude of the viral lysate samples for frequencies above 100 kHz was same as the impedance magnitude of the control samples (Fig. 2A). We observed that the maximum impedance magnitude shift for all HIV-1 subtypes with respect to control samples occurred at 1,000 Hz (Fig. 2A). Therefore, we chose this frequency to further statistically compare the impedance magnitude results. Fig. 2C shows the impedance magnitude of the viral lysate samples as well as control sample at 1,000 Hz. The impedance magnitude of the viral lysate samples was significantly lower than the impedance magnitude of the control samples (n = 3, p < 0.05), indicating that the captured and lysed viruses changed the electrical conductivity of the solution, thus can be detected using impedance spectroscopy (Fig. 2C). We also observed no significant difference between the impedance magnitudes of multiple HIV-1 subtypes (Figs. 2C and 2D, n = 3, p > 0.05), which indicated that this method of virus sensing was able to detect multiple HIV subtypes. The impedance magnitude of the viral lysate samples were also normalized with respect to the impedance magnitude of control samples at 1,000 Hz as shown in Fig. 2D. These results showed an impedance magnitude change of 20% to 30% compared with the control samples. The repeatability of the impedance magnitude measurements was observed to be between 88% and 99% (Fig. 2E and Supplementary Information). We evaluated the virus capture on magnetic beads conjugated with antibodies using green fluorescent protein (GFP)-tagged HIV-1 (Fig. S4). We also investigated the effect of time on the impedance magnitude of the viral lysate samples and we did not observe a significant difference in the impedance magnitude of the samples during the time of performing experiments (n = 3, p > 0.05) (Fig. S5).
To evaluate the specificity of this platform for HIV-1 detection, we used Epstein-Barr virus (EBV). The impedance magnitude spectra of HIV-1, EBV and the mixture of HIV-1 and EBV samples were measured and compared with control samples (Fig. 3A). Controls were virus-free DPBS samples. The impedance magnitude spectra of the HIV-1 and the mixture samples were lower compared to control and EBV samples (Fig. 3A). Further, the mean impedance magnitude spectrum of EBV samples was not significantly lower than control samples (Fig. 3A). The impedance magnitude of the samples was then analyzed at 1,000 Hz. The impedance magnitude of HIV-1 and the mixture of HIV-1 and EBV samples were significantly different compared to control samples at 1,000 Hz (Fig. 3B, n = 3, p < 0.05). The impedance magnitude of HIV-1 samples was not statistically different than the mixture of HIV-1 and EBV at 1,000 Hz (Fig. 3B, n = 3, p > 0.05). We also observed that the repeatability of these impedance magnitude measurements were between 79% and 99% (Fig. 3C).
To further evaluate the sensing ability of the platforms in complex biological samples, HIV samples were selectively isolated and detected from whole blood and plasma. Spiked viruses into whole blood and plasma samples were captured and isolated using biotinylated polyclonal anti-gp120 antibodies, washed 4 times with 20% glycerol solution and lysed for impedance spectroscopy detection (Fig. S6). The impedance magnitude spectra of the viral lysate samples are shown in Figs. S6A and S6B. The impedance magnitude of viral lysate samples were significantly lower compared to the impedance magnitude of control samples (whole blood and plasma without viruses) at 1,000 Hz and 1 V (Figs. 3D and 3E, n = 3, p < 0.05). The impedance magnitude shift in whole blood and plasma samples was found to be 13 ± 2% and 16 ± 5%, respectively (Fig. 3F). No significant difference was observed between the impedance magnitude shift in whole blood and plasma samples, indicating that the viruses were detected both in plasma and whole blood (Fig. 3F, n = 3, p > 0.05). Further, using higher sample volumes up to 5 mL increased the sensitivity of the platform, where the impedance magnitude of the viral lysate samples was significantly lower than control samples (virus-free DPBS samples) (Fig. S7, n = 3, p < 0.05). We were able to detect viruses using this polyester film-based electrical sensing platform in HIV-spiked DPBS samples with viral loads on the order of 106 copies/mL (Fig. S7).
Electrical sensing is a powerful modality to develop portable, rapid and sensitive diagnostic tools2,3,13,14,15. By employing polyester film as a flexible material, this label-free platform can potentially be used for the capture and detection of multiple pathogens with well-known biomarkers using impedance spectroscopy of their lysate. Here, we particularly present the ability of this platform to detect HIV-1 at the viral concentrations matching acute HIV-1 infection stage, where there is maximum virus reproduction (106–108 copies/mL) and minimum antibody concentration16. HIV-infected individuals can transmit the infection substantially during acute stage of HIV infection17. Thus, acute HIV-1 detection is crucial, where current rapid tests such as OraQuick or Determine HIV-1/2 Ag/Ab Combo rapid test cannot detect HIV infection due to low concentration of antibodies before the seroconversion and poor sensitivity to detect acute HIV in field studies16,18,19. These statistics clearly highlight the urgent and unmet clinical need for a POC viral load test for acute HIV detection20. Here, we have developed an inexpensive (less than $2 in material cost) (Table S1) and disposable electrical sensing platform on a flexible material (i.e., polyester film) to selectively capture and detect viruses (HIV-1) in clinical samples such as whole blood and plasma. However, this platform requires off-chip sample preparation including virus capture using antibodies, washing and virus lysis. By employing further developments in sample processing steps, this platform technology can be potentially automated for POC applications.
Bacteria detection and quantification on a cellulose paper-based nanoparticle aggregation substrate and image acquisition with a mobile phone
An ultra-sensitive biosensing platform was developed to detect pathogens through nanoparticle aggregation on a cellulose paper (Fig. 1B). The nanoparticle aggregation strategy was adapted as a sensing mechanism for detection of E. coli and S. aureus as model bacterial pathogens. In this platform, gold nanoparticles were first modified with specific recognition elements to capture pathogens in the solution. We subsequently transferred the modified nanoparticle solution to a disposable paper that allowed distribution of aggregated nanoparticles by utilizing capillary effect on its native structure. thus obtaining uniform distribution for quantitative analysis. To evaluate the chemical modifications on nanoparticle surface, 11-Mercaptoundeconoic acid (MUA), N-Ethyl-N'-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC)/N-hydroxysuccinimide (NHS) coupling agents and Lipopolysaccharide Binding Protein (LBP) for recognition of E. coli were used to modify gold nanoparticles. The maximum extinction wavelength peaks of nanoparticle colloids resulted in red-shifts after each surface modification (Fig. S8A). The conjugated nanoparticles were mixed with E. coli-spiked solutions and the nanoparticles then aggregated due to E. coli-nanoparticle interactions (Figs. S8B and S9). Collectively, the results in Fig. S8 demonstrated that the final morphology, structure and status of the nanoparticle aggregation was acutely triggered by the presence of E. coli in the solution, which caused a visible change in the color from red to blue.
To this end, the platform was validated by spiking E. coli into three distinct media: DPBS, whole blood serum and peritoneal dialysis (PD) fluid (Fig. 4). These three media without E. coli were used as controls. The blue color was obtained in E. coli-spiked samples and it was also distinguished from control samples (red color) (Fig. 4A). This color change in nanoparticles is associated with the interference of biomolecular interactions between the intermolecular interactions. Control experiments (E. coli-free samples in DPBS, whole blood serum and PD fluid) resulted in red-colored colloids of nanoparticles since there is no recognition site for LBP protein in the solution. Therefore, these experiments showed that blue color formation was not due to non-specific interactions and it was observed in the presence of target bacteria (E. coli). For quantitative analysis, the solution containing modified nanoparticles and bacteria was also sampled and dried on a paper within 10 minutes and a mobile phone camera (Sony Ericson i790) was then employed as an image acquisition step for nanoparticle aggregate spots (Fig. 1B). Further, the ability to detect E. coli with a naked eye was confirmed by measuring the intensity with a customized imaging analysis tool on the computer, which provided color intensities of images using a customized MATLAB code in terms of red (R), green (G) and blue (B) pixel values as previously presented21. Briefly, the code was used (i) to obtain RGB pixel values and (ii) to calculate color intensity for each image. In these experiments, R value allowed a broader color intensity range and thus, we continued to employ R values for measurements. The area of interest was manually selected in the middle of nanoparticle aggregate spots with ~0.25 cm2 on the cellulose paper surface. Further, as we demonstrated previously21,22, this code can also be adapted to a mobile phone application for automatic region selection (given a specific region is marked on the paper) and analysis.
To evaluate the limit of detection, control and E. coli samples were analyzed using statistical methods and the lowest detectable concentration was observed to be 8 colony forming units (CFUs)/mL for all samples (Fig. 4B–D). These results demonstrated the employment of the nanoparticle aggregation approach-operated on a cellulose paper for the detection and identification of pathogens at low concentrations. For multiplexing and specificity experiments, we designed three sets of experiments: (i) the sampling of S. aureus (105 CFUs/mL) into anti-LTA antibody-modified gold nanoparticle solution, (ii) the sampling of E. coli (105 CFUs/mL) into anti-LTA antibody-modified gold nanoparticle solution and (iii) the sampling of mixed bacteria (S. aureus (105 CFUs/mL) and E. coli (105 CFUs/mL)) into anti-LTA antibody-modified gold nanoparticle solution (Fig. 4E). From multiplexing perspective, S. aureus-spiked samples presented statistically different results than that of E. coli-spiked samples (n = 5, p < 0.05) (Fig. 4E). Further, we observed a minimal cross-reactivity (non-specific binding) against E. coli that is statistically smaller than the data in mixture samples (n = 5, p < 0.05) (Fig. 4E). At the third set of experiments, we evaluated the specificity performance of the platform with mixed samples. Statistical analysis demonstrated that there was no significant difference between the results obtained from S. aureus and mixture samples (n = 5, p > 0.05) (Fig. 4E). Since there is no notable interaction between anti-LTA antibody-modified gold nanoparticles and E. coli, the color intensity originated due to S. aureus confirmed selective capture and detection of S. aureus from the mixed samples (Fig. 4E). In addition, to assess the MATLAB code performance for analysis, S. aureus experiments were further evaluated with other mobile phones such as iPhone 4, Samsung i9300 Galaxy S3 and HTC Vivid, which have different cameras for the image acquisition (Fig. 4F). Without any modification on the code, we did not observe any statistical difference between the results obtained from various mobile phone cameras (n = 5, p > 0.05). Overall, we demonstrated a specific and multiplexed platform for the detection of different bacterial pathogens using an unconventional nanoparticle aggregation approach incorporated with cellulose paper.
From a diagnostics perspective, colorimetric ELISA-based detection assays are currently employed as a conventional laboratory method, where the corresponding detection signal is formed by the conversion of enzyme substrate into a colored product and the signal intensity is measured using a spectroscopic plate reader21. Although the color changes can be distinguished by a naked eye, these assays require multiple operational steps and expensive infrastructure. In our assay, the formation of colored solutions is employed to quantitatively detect target pathogens such as E. coli and S. aureus. In this platform, the nanoparticle aggregation is associated with the repulsive electrostatic forces between nanoparticles and resulted in a blue color in the presence of the pathogens (Fig. 1B)23,24. Therefore, the solution absorbs the light at longer wavelengths compared to non-aggregated form25. The blue and red colors are simply distinguished at a glance; thus, the presence of pathogens are detected with the naked eye and it is further quantitatively analyzed using an image analysis tool coupled with image acquisition from a mobile phone. Thus, the current platform offers a simpler and inexpensive alternative to traditional detection methods. However, labeling with antibodies and peptides are still needed for the detection of biotargets. By employing new binders including carbohydrates and other biological recognition elements, this detection strategy will potentially be tailored to other POC applications in the resource-constrained settings.
From bacterial infection perspective, E. coli and S. aureus are the most common bacterial pathogens that pose significant clinical threats including food poisoning, skin infections and sepsis at low concentrations (10–1,000 CFUs/mL)26,27,28. Further, E. coli is reported as one of the most common species for bacterial infection observed in PD patients29,30. Here, E. coli spiked in PD samples were used as a clinical disease model. In end-stage renal disease (ESRD) patients, kidney replacement or dialysis to preserve any residual renal function is required. It is estimated that more than half a million patients will require dialysis in 2020 with the rising disease prevalence in the US31. However, a barrier in the clinical practice for broad adaption for PD has been the risk of peritonitis, i.e., inflammation of the peritoneum. Peritonitis has to be detected early and treated before it becomes a chronic case. Detecting bacterial infection offers a great promise for the early diagnosis of peritonitis as well as other bacteria-induced diseases such as sepsis26 and ventilator-associated pneumonia32 at the bedside and resource-constrained settings, where time consuming and expensive assays such as cell cultures, ELISA and nucleic acid-based tests may not be available.
CD4+ T lymphocyte capture and detection on a flexible polyester film-based imaging platform
A flexible polyester film with microfluidic channels was employed to selectively and efficiently capture and quantify cells of interest in unprocessed whole blood samples. Here, we evaluated this platform to capture and quantify CD4+ T lymphocytes in fingerprick whole blood samples for POC HIV diagnosis as a clinical disease model (Fig. 1C). We have evaluated ten different flexible substrates to fabricate microfluidic devices for capturing and counting CD4+ T cells from whole blood. We also evaluated these substrates for optical compatibility with wide-field of view lensless imaging on a complementary metal-oxide-semiconductor (CMOS) sensor. These flexible substrates are polyester-based transparency films that are routinely used for printing and lamination. All substrates were first imaged using bright-field (BF) microscopy to visualize any inbuilt debris (Fig. S10). Some of these substrates such as 3M, 7333 Hostaphan®, 2262N Hostaphan®, 2261N Hostaphan® and Grafix showed debris and small inbuilt particles that could hinder detection of captured cells. As captured CD4+ T cells were stained with fluorescent dyes, we first evaluated these substrates for autofluorescence at various wavelengths (blue, green and red regions) using a fluorescent microscope (Fig. S10). The substrates having large number of inbuilt debris particles also showed higher autofluorescence when samples were imaged using a fluorescent microscope (Fig. S10). To quantify the autofluorescence intensity of these images, we calculated the mean autofluorescence intensity of substrates using NIH ImageJ software (http://rsb.info.nih.gov/nih-image/). The intensity histograms, corresponding microscope images and the mean intensity plots were demonstrated in Figures S10 and S11. Here, we used a glass slide as a standard substrate for this characterization. The substrate that showed comparable autofluorescence characteristics with glass substrates was chosen for the device assembly and thus, 3915 300ga Hostaphan® material was used for further studies (Fig. 5A). Although 3915 Hostaphan® material resulted in higher autofluorescence at DAPI excitation, this autofluorescence was not high enough to block the strong DAPI signal. Comparing the substrate autofluorescence in green (GFP) and red (CY5) excitation, we observed that 3915 Hostaphan® material showed lesser autofluorescence in red excitation. The autofluorescence difference between glass and 3915 Hostaphan® material at red excitation was also less as compared to green excitation (Fig. 5A).
For the capture of CD4+ T cells, this flexible platform was assembled and functionalized to immobilize the capture antibody (Fig. 1C). To optimize the surface chemistry, we have used various concentrations of NeutrAvidin-conjugated-FITC (NA-FITC) after N-gamma-Maleimidobutyryl-oxysuccinimide ester (GMBS) functionalization step ranging from 0.1 mg/mL to 1 mg/mL. We observed an increase in fluorescent intensity up to 0.5 mg/mL NA-FITC concentration. We then selected 0.5 mg/mL NA-FITC concentration for further experiments as the fluorescent intensity saturated beyond this concentration (Fig. 5B). The assembled devices were further functionalized with various concentrations of anti-CD4 capture antibody (5, 10 and 20 μg/mL). A drop of whole blood (10 μL) was sampled into the inlet of microfluidic channels of the platform. The blood filled the whole channel due to capillary forces, without using a micro-pump (Movie S1). The flexible film-based devices were bent up and down to mix the blood inside the channels to enhance cell surface interactions to improve cell capture (Movie S2). DAPI staining was used to stain nucleated white blood cells (WBCs), whereas Alexa Flour 647 (AF647) anti-CD4 antibody was used to stain captured CD4+ T cells. The surfaces were imaged using a fluorescent microscope and cell capture efficiency and specificity were calculated (Supplementary Information). The bright-field and fluorescent images of the captured cells are shown in Fig. 5C. Captured WBCs and CD4+ T cells can be observed clearly through the flexible substrate. The CD4+ T cell capture efficiencies were 51.8% ± 13.5%, 64.0% ± 10.1% and 66.7% ± 10.7% for devices functionalized with 5, 10 and 20 μg/mL capture antibody, respectively (Fig. 5D). The CD4+ T cell capture specificities were 85.2% ± 5.0%, 75.7% ± 4.8% and 76.0% ± 5.1% for devices functionalized with 5, 10 and 20 μg/mL capture antibody, respectively (Fig. 5E). We observed that increasing the capture antibody concentration increased the CD4+ T cell capture efficiency and reduced the capture specificity. Here, this flexible material (i.e., polyester film)-based platform can be integrated with CMOS lensless imaging platform for rapid detection of CD4+ T cells (Fig. S12A). Shadows of the captured cells are imaged by lensless sensor in a few seconds (Figs. 1C (iv) and S12B–C). The CMOS sensor allowed rapid cell detection without using a fluorescent tag. However, transparency films/substrates with higher clarity and quality would enhance captured cell shadow contrast for quantification. Overall, the developed platform allows efficient CD4+ T cell counting using fingerprick volume of unprocessed whole blood samples at the POC. These results indicate that the platform has the potential to replace conventional non-disposable glass-based rigid biosensing devices in the future given that the capture efficiency and specificity are further increased beyond 90% by further optimization of the materials and optical properties of the films as a substrate. In the current form, the device processing requires manual pipetting steps for blood injection and channel washing, but the developed platform can potentially be made fully automated by integrating microfluidic devices to disposable cartridges.
From HIV diagnostic perspective, accurate CD4+ T cell count is essential for HIV-1 diagnosis and treatment monitoring33,34,35. Current World Health Organization (WHO) guidelines recommend antiretroviral therapy (ART) for individuals with CD4+ T cell count of less than 500 cells/μl36. Conventional CD4+ T cell counting methods require flow cytometer, i.e., a gold standard method, for CD4+ T cell counting in the developed world. This method, however, requires a skilled operator, expensive infrastructure and reagents. The disposable and flexible biosensing platform for efficient counting of CD4+ T cells has potential to address some of these global health challenges at the POC settings.
Paper and flexible material-based biosensing platforms are powerful tools to create affordable and disposable POC disease detection and treatment monitoring assays, particularly for the resource-constrained settings. There is a need for their integration with different detection strategies for distinct biotargets from multiple biological and clinical matrices such as whole blood, serum, saline buffer, dialysis effluent or lysates with high sensitivity and specificity. In this manuscript, as clinical models, we demonstrated the isolation and detection of HIV-1 CD4+ T lymphocytes, E. coli and S. aureus in various matrices including whole blood, plasma and peritoneal dialysis fluid. We also reported various cellulose paper and flexible substrate-based platforms allowing broadly applicable diagnostic assays through seamlessly integrating optical and electrical sensing modalities. Thus, these various platforms are uniquely able to isolate and detect multiple biotargets selectively, sensitively and repeatably from diverse biological matrices using antibodies and peptides. Further, these platforms could potentially be adapted and tailored to detect other pathogens and biotargets with well-known biomarkers13,34,37,38,39,40,41,42.
Yetisen, A. K., Akram, M. S. & Lowe, C. R. Paper-based microfluidic point-of-care diagnostic devices. Lab Chip 13, 2210–2251 (2013).
Shafiee, H., Caldwell, J. L., Sano, M. B. & Davalos, R. V. Contactless dielectrophoresis: a new technique for cell manipulation. Biomed Microdevices 11, 997–1006 (2009).
Shafiee, H., Sano, M. B., Henslee, E. A., Caldwell, J. L. & Davalos, R. V. Selective isolation of live/dead cells using contactless dielectrophoresis (cDEP). Lab Chip 10, 438–445 (2010).
Lissandrello, C. et al. Nanomechanical motion of Escherichia coli adhered to a surface. Applied physics letters 105, 10.1063/1.4895132 (2014).
Sevimli, S., Inci, F., Zareie, H. M. & Bulmus, V. Well-defined cholesterol polymers with pH-controlled membrane switching activity. Biomacromolecules 13, 3064–3075 (2012).
Whitesides, G. M. Cool, or simple and cheap? Why not both? Lab Chip 13, 11–13 (2013).
Blow, N. Microfluidics: the great divide. Nat Methods 6, 683–686 (2009).
Martinez, A. W., Phillips, S. T., Whitesides, G. M. & Carrilho, E. Diagnostics for the developing world: microfluidic paper-based analytical devices. Anal Chem 82, 3–10 (2010).
Yager, P. et al. Microfluidic diagnostic technologies for global public health. Nature 442, 412–418 (2006).
Zhu, Y. et al. Cellulose Paper Sensors Modified with Zwitterionic Poly(carboxybetaine) for Sensing and Detection in Complex Media. Anal Chem 86, 2871–2875 (2014).
Costa, M. et al. A low cost, safe, disposable, rapid and self-sustainable paper-based platform for diagnostic testing: lab-on-paper. Nanotechnology 25, 10.1088/0957-4484/25/9/094006 (2014).
Li, W. et al. Multiplex electrochemical origami immunodevice based on cuboid silver-paper electrode and metal ions tagged nanoporous silver-chitosan. Biosensors & bioelectronics 56, 167–173 (2014).
Shafiee, H. et al. Acute On-Chip HIV Detection Through Label-Free Electrical Sensing of Viral Nano-Lysate. Small 9, 2553–2563 (2013).
Salmanzadeh, A. et al. Isolation of prostate tumor initiating cells (TICs) through their dielectrophoretic signature. Lab Chip 12, 182–189 (2012).
Shafiee, H., Caldwell, J. & Davalos, R. A Microfluidic System for Biological Particle Enrichment Using Contactless Dielectrophoresis. JALA 15, 224–232 (2010).
Daar, E. S., Moudgil, T., Meyer, R. D. & Ho, D. D. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 324, 961–964 (1991).
Powers, K. A. et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 378, 256–268 (2011).
Laperche, S., Leballais, L., Ly, T. D. & Plantier, J. C. Failure in the Detection of HIV p24 Antigen with the Determine HIV-1/2 Ag/Ab Combo Rapid Test. J Infect Dis 206, 1946–1947 (2012).
Rosenberg, N. E. et al. Detection of acute HIV infection: a field evaluation of the determine(R) HIV-1/2 Ag/Ab combo test. J Infect Dis 205, 528–534 (2012).
Shafiee, H. et al. Nanostructured Optical Photonic Crystal Biosensor for HIV Viral Load Measurement. Sci Rep 4, 4116; 10.1038/srep04116 (2014).
Wang, S. et al. Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care. Lab Chip 11, 3411–3418 (2011).
Wang, S. et al. Micro-a-fluidics ELISA for Rapid CD4 Cell Count at the Point-of-Care. Sci. Rep. 4, 3796; 10.1038/srep03796 (2014).
Rosicka, D. & Sembera, J. Changes in the nanoparticle aggregation rate due to the additional effect of electrostatic and magnetic forces on mass transport coefficients. Nanoscale Res Lett 8, 20; 10.1186/1556-276X-8-20 (2013).
Bennett, S. W., Zhou, D., Mielke, R. & Keller, A. A. Photoinduced Disaggregation of TiO2 Nanoparticles Enables Transdermal Penetration. Plos One 7, 10.1371/journal.pone.0048719 (2012).
Levy, R. et al. Rational and combinatorial design of peptide capping Ligands for gold nanoparticles. J Am Chem Soc 126, 10076–10084 (2004).
Wang, S. et al. Portable microfluidic chip for detection of Escherichia coli in produce and blood. Int J Nanomed 7, 2591–2600 (2012).
Willshaw, G. A. et al. Vero cytotoxin-producing Escherichia-coli O157 in beefburgers linked to an outbreak of diarrhea, hemorrhagic colitis and hemolytic-uremic syndrome in Britain. Lett Appl Microbiol 19, 304–307 (1994).
Moorman, J. P. & Salgado, C. D. Gantz's Manual of Clinical Problems in Infectious Disease. (Lippincott Williams & Wilkins, 2012).
Mactier, R. Peritonitis is still the achilles' heel of peritoneal dialysis. Periton Dialysis Int 29, 262–266 (2009).
Szeto, C. C. et al. Enterobacteriaceae peritonitis complicating peritoneal dialysis: A review of 210 consecutive cases. Kidney Int 69, 1245–1252 (2006).
Collins, A. J., Foley, R. N., Gilbertson, D. T. & Chen, S. C. The state of chronic kidney disease, ESRD and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephro 4 Suppl 1, S5–11 (2009).
Durmus, N. G. et al. Fructose-enhanced reduction of bacterial growth on nanorough surfaces. International journal of nanomedicine 7, 537–545 (2012).
Wang, S., Xu, F. & Demirci, U. Advances in developing HIV-1 viral load assays for resource-limited settings. Biotechnol Adv 28, 770–781 (2010).
Moon, S. et al. Enumeration of CD4+ T-cells using a portable microchip count platform in Tanzanian HIV-infected patients. PLoS One 6, e21409; 10.1371/journal.pone.0021409 (2011).
Shafiee, H. et al. Emerging Technologies for Point-of-Care Management of HIV Infection. Annu Rev Med 66, 387–405 (2015).
World Health Organization, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed on September 19, 2014. (2013).
Inci, F. et al. Nanoplasmonic Quantitative Detection of Intact Viruses from Unprocessed Whole Blood. ACS Nano 7, 4733–4745 (2013).
Wang, S. et al. Efficient on-chip isolation of HIV subtypes. Lab Chip 12, 1508–1515 (2012).
Tokel, O., Inci, F. & Demirci, U. Advances in Plasmonic Technologies for Point of Care Applications. Chem Rev 114, 5728–5752 (2014).
Mani, V. et al. Emerging Technologies for Monitoring Drug-Resistant Tuberculosis at the Point-of-Care. Adv Drug Deliver Rev 78, 105–117 (2014).
Tasoglu, S., Gurkan, U. A., Wang, S. & Demirci, U. Manipulating biological agents and cells in micro-scale volumes for applications in medicine. Chem Soc Rev 42, 5788–5808 (2013).
Yildiz, U. H. et al. Recent advances in micro/nanotechnologies for global control of hepatitis B infection. Biotechnology Advances 10.1016/j.biotechadv.2014.11.003 (2014).
We would like to acknowledge NIH R01AI093282, NIH R01GM086382, NIH U54EB15408, NIH R21AI087107, F32AI102590 and Brigham and Women's Hospital BRI Translatable Technologies and Care Innovation Grant. We also thank The Scientific and Technical Research Council of Turkey (TUBITAK) for providing financial support (2214A - Abroad research support for Ph.D. students) to M. Yuksekkaya during his visit to BAMM Labs, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.
Yes, there is a potential competing financial interest. Dr. U. Demirci is a founder of and has an equity interest in: (i) DxNow Inc., a company that is developing microfluidic and imaging technologies for point-of-care diagnostic solutions and (ii) Koek Biotech, a company that is developing microfluidic IVF technologies for clinical solutions. Dr. U. Demirci's interests were viewed and managed by the Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict-of-interest policies.
Electronic supplementary material
About this article
Cite this article
Shafiee, H., Asghar, W., Inci, F. et al. Paper and Flexible Substrates as Materials for Biosensing Platforms to Detect Multiple Biotargets. Sci Rep 5, 8719 (2015). https://doi.org/10.1038/srep08719
This article is cited by
Diagnostic assay and technology advancement for detecting SARS-CoV-2 infections causing the COVID-19 pandemic
Analytical and Bioanalytical Chemistry (2022)
Analytical and Bioanalytical Chemistry (2022)
Biomedical Microdevices (2022)
Hand-drawn electrode based disposable paper chip for artificial sweat analysis using impedance spectroscopy
Biomedical Microdevices (2021)